Our study has limitations. First, the repigmentation could be attributable in part to the concurrent use of topical tacrolimus. Second, the sample population was small. Third, patient satisfaction has not been investigated in this study.
The microbial flora of taxane therapyeassociated nail disease in cancer patients See related letter on page e71
To the Editor: Taxanes are frequently associated with nail and periungual tissue afflictions such as paronychia, onychodystrophy, onycholysis, subungual hemorrhages, and pyogenic granulomas. 1 These therapy-associated nail abnormalities can cause physical symptoms and psychosocial distress, leading to impairments in patients' quality of life. The changes in quality of life may affect the number of therapy cycles that a patient can tolerate, and in some cases, they may lead to discontinuation of anticancer therapy. 2 We conducted a retrospective chart review ( from August 2012 to June 2015) of paclitaxeland docetaxel-treated patients referred to a dermatologist (M.E.L.). The majority of the 114 patients were women with breast cancer in whom paclitaxel-associated acute paronychia had developed (Table I ). The clinical severity of the nail infections and changes was mostly grade 2, which is consistent with moderately severe adverse events requiring local, noninvasive interventions (Common Terminology Criteria for Adverse Events, version 4.0 3 [ Table II] ). We did not identify any grade 3 or 4 nail abnormalities, suggesting that medically significant adverse events may require prompt interruption of anticancer therapy and are therefore less likely to be seen in the outpatient setting.
Microbiological cultures grew 21 distinct bacterial and fungal species (Fig 1) . The most commonly isolated organism, Staphylococcus aureus, is a part of resident skin flora. In patients with cancer, however, it is associated with high morbidity and mortality rates. 4 Nearly half of the isolates in these patients were opportunistic and/or pathogenic organisms (nonskin flora). This is reflective of the combined role of impaired resistance to colonization because of taxane therapy and exposure to health care environments, in which the acquisition of these organisms is more likely. In general, direct cytotoxic, antiangiogenic, or neurotropic effects of taxanes in the nail matrix appear to be the inciting factors, with a positive correlation with the number of treatment cycles (cumulative dose). In the setting of an impaired physical barrier owing to the antimitotic effect of taxanes in the nail matrix and suppression of the innate and adaptive immune responses related to systemic cytotoxic anticancer therapies, we hypothesize that these infectious agents may be responsible for nail abnormalities in some patients. In 46 patients (40.4%), the culture sensitivity results necessitated treatment modifications. The most prescribed oral antibiotics were cefadroxil, ciprofloxacin, and sulfamethoxazole-trimethoprim. The most prescribed topical antimicrobials were ciclopirox, bacitracin-polymyxin b, and iodine. At follow-up, 80.5% of patients reported clinical improvement in their condition (Table III) .
In the population of patients with cancer, we recommend routinely collecting bacterial and fungal culture swabs from affected periungual tissues. We propose empiric oral antibiotic treatment with fluoroquinolones or first-or second-generation cephalosporins in conjunction with topical antimicrobials. In the experience of 1 of the authors (M.E.L.), extended therapy (4-6 weeks) is often required, perhaps on account of poor penetration of antibiotics into affected tissues and the risk of treatment failure with shorter courses (# 2 weeks). Of note, nail infections and other nail changes are likely to recur if taxane therapy is ongoing. Instituting frozen gel sock and/or glove therapy for 15 minutes before, 60 minutes during, and 15 minutes after taxane infusion reduces the incidence of nail pathology. 5 Patients will need routine supportive oncodermatology monitoring. 
